SAINT LOUIS, MO – August 14, 2014 – Sigma-Aldrich Corporation (NASDAQ: SIAL) is pleased to announce that the Cerilliant® brand within its Applied Diagnostics and Testing business segment now offers nine new stable isotope-labeled internal standards of 2C amines including deuterium and 13C labeling. These Certified Reference Materials (CRMs) represent the latest addition to Cerilliant’s extensive CRM line of New Psychoactive Substance CRMs.     

The stable-label substitutions of each internal standard correspond to suitable locations for conserving a minimum [M+3] separation from the unlabeled in the major ion fragments used in GC/MS or LC-MS/MS phenethylamine analytical methods.

 

“Internal standard design is an important consideration during the early stages of product development to ensure the label placement is suitable for our customers’ methods,” said H. Kenan Yaser, Manager, Synthesis Operations. “Our design process includes an evaluation of the native compound’s major ion fragments by mass spec to understand the preferred locations for placement of the stable-label ensuring accurate and reliable results for laboratories.” 

 

For added convenience, Cerilliant’s 2C amine internal standard reference solutions are supplied as USDEA-exempt preparations since these compounds are classified as controlled substances in the U.S. These solution CRMs are suitable for use in isotope dilution methods or other quantitative applications in clinical toxicology, urine drug testing, forensic analysis, or workplace drug screening. Cerilliant Certified Spiking Solutions® are manufactured and certified to the highest industry standards including ISO Guide 34, ISO/IEC 17025, ISO 15194 and ISO 13485.

 

Phenethylamines are a class of compounds with documented psychedelic and stimulant effects. The 2C series of phenethylamines has been well known since the 1970s from the synthetic work and authorship of Alexander Shulgin. Over the last few years, abuse of 2C amine designer drugs has increased worldwide from Asia to the United States and Europe as legal and illicit alternatives to MDMA or Ecstasy.¹

 

1.  Dean BV, Stellpflug SJ, Burnett AM, Engebretsen KM. 2C or not 2C: phenethylamine designer drug review. J Med Toxicol. 2013;9(2):172–178.